Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 5, 2002, Pages 505-513

  Ridtitid, Wibool ^a   Wongnawa, Malinee ^a   Mahatthanatrakul, Werawath ^a   Punyo, Jarurat ^a   Sunbhanich, Methi ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; PRAQUANTEL; PRAZIQUANTEL; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CLONORCHIS SINENSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG HALF LIFE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MULTIPLE DRUG DOSE; MYCOBACTERIUM TUBERCULOSIS; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THAILAND; VOLUNTEER;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MALE; PRAZIQUANTEL; RIFAMPIN;

EID: 0036881632     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.129319     Document Type: Article

References (30)

1. Goldsmith RS. Clinical pharmacology of the anthelmintic drugs. In: Katzung BG, editor. Basic & clinical pharmacology. 8th ed. New York: McGraw-Hill; 2001. p. 903-22.
2. Tracy JW, Webster LT Jr. Drugs used in the chemotherapy of helminthiasis. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 1009-26.
3. Khamboonruang C. On emerging problems in food-borne parasitic zoonosis: impact on agriculture and public health. Southeast Asian J Trop Med Public Health 1991; 22(Suppl):1-7.
4. Jongsuksuntigul P, Imsomboon T. Epidemiology of opisthorchiasis and national control program in Thailand. Southeast Asian J Trop Med Public Health 1998;29:327-32.
5. Bittencourt PR, Bracia CM, Marlins R, Fernandes AG, Diekmann HW, Jung W. Phenytoin and carbamazepine decreased oral bioavailability of praziquantel. Neurology 1992;42:492-6.
6. Dachman WD, Adubofour KO, Bikin DS, Johnson CH, Mullin PD, Winograd M. Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. J Infect Dis 1994;169:689-91.
7. World Health Organization. Tuberculosis fact sheet. Global Tuberculosis Program; 1998.
8. Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 2001;40:833-68.
9. Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992;22:47-65.
10. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-7.
11. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59:7-13.
12. Villikka K, Kivisto KT, Backman JT, Olkkola KT, Neuvonen PJ. Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 1997;61:8-14.
13. Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ. Tamoxifen and toremifene concentrations in plasma are greatly deceased by rifampin. Clin Pharmacol Ther 1998;64:48-54.
14. Villikka K, Kivisto KT, Neuvonen PJ. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther 1999;65:377-81.
15. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Chaipol P, Sunbhanich M. Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. J Pharm Pharmacol 2000;52:1265-9.
16. Masimirembwa CM, Hasler JA. Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors. Biochem Pharmacol 1994;48:1779-83.
17. Xiao S-H, Catto BA, Webster LT Jr. Quantitative determination of praziquantel in serum by high-performance liquid chromatography. J Chromatogr 1983;275:127-32.
18. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, Sunbhanich M. LC determination of praziquantel in human plasma. J Pharm Biomed Anal 2002;28:181-6.
19. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.
20. Leopold G, Unguthem W, Groll E, Diekmann HW, Nowak H, Wegner DHG. Clinical pharmacology in normal volunteers of praziquantel. A new drug against schistosomes and cestodes. Eur J Clin Pharmacol 1978;14:281-91.
21. el Mandour MM, el Turabi H, Homeida MMA, el Sadig T, Ali HM, Bennett JL, et al. Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Trans R Soc Trop Med Hyg 1990;84:389-93.
22. Watta G, White NJ, Padre L, Ritter MT, Fernando MT, Ranoa CP, et al. Praziquantel pharmacokinetics and side effects in Schistosoma japonicum-infected patients with liver disease. J Infect Dis 1988;157:530-5.
23. Ofori-Ajei D, Adjepon-Yamoah KK, Lindstrom B. Oral praziquantel kinetics in normal and schistosomiasis haematobium infected subjects. Ther Drug Monit 1988;10:45-50.
24. Andrews P. In: Jackson GG, Schlumberger HD, Zeiler HJ, editors. Perspectives in antiinfective therapy. Proceedings of an international symposium. August 31-September 3, 1988; Washington, DC. Braunschweig: Vieweg; 1999. p. 68-72.
25. Patzschke K, Putter J, Wagner LA, Horster FA, Diekmann HW. Serum concentrations and renal excretion in humans after oral administration of praziquantel. Results of three determination methods. Eur J Drug Metab Pharmacokinet 1979;3:149-56.
26. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996;24:796-801.
27. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
28. Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano JP, et al. Metabolism of cyclosporin A. IV. purification and identification of rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidases) as a product of P450 IIIA gene subfamily. Drug Metab Dispos 1989;17:197-207.
29. Lamberg TS, Kivisto K, Neuvonen PJ. Concentrations and effects of buspirone are considerably reduced by rifampicin. Br J Clin Pharmacol 1998;45:381-5.
30. Castro N, Medina R, Sotelo J, Jung H. Bioavailability of praziquantel increase with concomitant administration of food. Antimicrob Agent Chemother 2000;44:2903-4.